Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

111 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Pöstlberger S, Menzel C, Jakesz R, Seifert M, Hubalek M, Bjelic-Radisic V, Samonigg H, Tausch C, Eidtmann H, Steger G, Kwasny W, Dubsky P, Fridrik M, Fitzal F, Stierer M, Rücklinger E, Greil R; ABCSG-12 Trial Investigators, Marth C. Gnant M, et al. N Engl J Med. 2009 Feb 12;360(7):679-91. doi: 10.1056/NEJMoa0806285. N Engl J Med. 2009. PMID: 19213681 Clinical Trial.
Chemotherapeutic treatment of a pregnant patient with ovarian dysgerminoma.
Hubalek M, Smekal-Schindelwig C, Zeimet AG, Sergi C, Brezinka C, Mueller-Holzner E, Marth C. Hubalek M, et al. Arch Gynecol Obstet. 2007 Aug;276(2):179-83. doi: 10.1007/s00404-007-0328-2. Arch Gynecol Obstet. 2007. PMID: 17342499
Development and validation of a liquid chromatography-tandem mass spectrometry method for the simultaneous quantification of tamoxifen, anastrozole, and letrozole in human plasma and its application to a clinical study.
Beer B, Schubert B, Oberguggenberger A, Meraner V, Hubalek M, Oberacher H. Beer B, et al. Anal Bioanal Chem. 2010 Oct;398(4):1791-800. doi: 10.1007/s00216-010-4075-z. Epub 2010 Aug 22. Anal Bioanal Chem. 2010. PMID: 20730580
Is the toxicity of adjuvant aromatase inhibitor therapy underestimated? Complementary information from patient-reported outcomes (PROs).
Oberguggenberger A, Hubalek M, Sztankay M, Meraner V, Beer B, Oberacher H, Giesinger J, Kemmler G, Egle D, Gamper EM, Sperner-Unterweger B, Holzner B. Oberguggenberger A, et al. Breast Cancer Res Treat. 2011 Jul;128(2):553-61. doi: 10.1007/s10549-011-1378-5. Epub 2011 Feb 11. Breast Cancer Res Treat. 2011. PMID: 21311968
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial.
Gnant M, Mlineritsch B, Stoeger H, Luschin-Ebengreuth G, Heck D, Menzel C, Jakesz R, Seifert M, Hubalek M, Pristauz G, Bauernhofer T, Eidtmann H, Eiermann W, Steger G, Kwasny W, Dubsky P, Hochreiner G, Forsthuber EP, Fesl C, Greil R; Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria. Gnant M, et al. Lancet Oncol. 2011 Jul;12(7):631-41. doi: 10.1016/S1470-2045(11)70122-X. Epub 2011 Jun 5. Lancet Oncol. 2011. PMID: 21641868 Clinical Trial.
[Guideline for the prevention and early detection of breast and ovarian cancer in high risk patients, particularly in women from HBOC (hereditary breast and ovarian cancer) families].
Singer CF, Tea MK, Pristauz G, Hubalek M, Rappaport C, Riedl C, Helbich T. Singer CF, et al. Wien Klin Wochenschr. 2012 May;124(9-10):334-9. doi: 10.1007/s00508-012-0173-6. Epub 2012 May 28. Wien Klin Wochenschr. 2012. PMID: 22644217 German.
111 results
Jump to page
Feedback